REGENXBIO Inc. (RGNX) has a consensus analyst rating of Buy, based on 20 analysts covering the stock. Of those, 14 recommend buying, 5 recommend holding, and 1 recommend selling.
The analyst consensus price target for RGNX is $26.00, representing a +179.6% upside from the current price of $9.3. Price targets range from a low of $12.00 to a high of $45.00.
